Advertisement

Advertisement

2019 Transplantation & Cellular Therapy (TCT) Meetings

Hematologic Malignancies

PRIMeR Study Explores Meaning of Minimal Residual Disease in Myeloma

In a study that earned a Best Abstract Award at the 2019 Transplantation & Cellular Therapy (TCT) Meetings in Houston, minimal residual disease (MRD) negativity at 1 year after autologous hematopo...

Advertisement

Advertisement



;
Advertisement